Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 12/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20435011 | 1.00 | SLC29A1 (0.56) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL24505864 | 0.93 | SLC29A1 (0.57) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL20434965 | 0.84 | SLC29A1 (0.74) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL20434964 | 0.84 | SLC29A1 (0.74) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL20434985 | 0.82 | SLC29A1 (0.70) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL24505763 | 0.82 | SLC29A1 (0.70) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL20435043 | 0.81 | SLC29A1 (0.69) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL20435042 | 0.81 | SLC29A1 (0.69) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL20435031 | 0.80 | SLC29A1 (0.72) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL24505811 | 0.80 | ADORA3 (0.44) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753432-B2 | Compound with analgesic effect for use in prevention and treatment of pain | ACADEMIA SINICA (TW) | 2023-09-12 | — | — | US | disclosed |
| EP-3573996-B1 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | ACADEMIA SINICA (TW) | 2022-06-15 | — | — | EP | disclosed |
| WO-2018140734-A1 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | ACADEMIA SINICA (TW) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753432-B2 | Compound with analgesic effect for use in prevention and treatment of pain | ADORA2B, ADORA1, ADORA3 | SLC29A1 347/4885TP53 3681/4885CYP3A4 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.